Mar 28, 2022 8:00am EDT Inhibikase Therapeutics to Participate in the Next Generation Kinase Inhibitors Summit
Mar 25, 2022 8:00am EDT Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022
Mar 23, 2022 8:00am EDT Inhibikase Therapeutics to Participate in the Maxim Group 2022 Virtual Growth Conference
Mar 08, 2022 8:00am EST Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD™ Alzheimer's & Parkinson's Diseases Conference
Nov 29, 2021 8:05am EST Inhibikase Therapeutics Announces Publication Highlighting Mechanism of Disease and the Potential of Oral c-Abl Kinase Inhibitor Therapy for the Treatment of Parkinson's Disease
Nov 15, 2021 5:30pm EST Inhibikase Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
Oct 27, 2021 8:05am EDT Inhibikase Therapeutics to Participate in Upcoming Michael J. Fox Foundation Alpha-Synuclein Summit
Oct 19, 2021 8:05am EDT Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009
Oct 04, 2021 8:05am EDT Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson's Disease